Aptose Biosciences (NASDAQ:APTO) Earns Hold Rating from Analysts at StockNews.com

StockNews.com assumed coverage on shares of Aptose Biosciences (NASDAQ:APTO) (TSE:APS) in a research report sent to investors on Sunday morning. The brokerage issued a hold rating on the biotechnology company’s stock.

Aptose Biosciences Stock Up 2.9 %

NASDAQ:APTO opened at $0.40 on Friday. Aptose Biosciences has a 52-week low of $0.33 and a 52-week high of $3.32. The stock’s 50 day moving average price is $0.40 and its 200 day moving average price is $0.74. The company has a market capitalization of $7.24 million, a PE ratio of -0.06 and a beta of 1.26.

Aptose Biosciences (NASDAQ:APTO) (TSE:APS) last announced its earnings results on Thursday, August 8th. The biotechnology company reported ($0.43) EPS for the quarter, beating analysts’ consensus estimates of ($0.58) by $0.15.

Institutional Trading of Aptose Biosciences

A hedge fund recently bought a new stake in Aptose Biosciences stock. Armistice Capital LLC acquired a new stake in Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 1,713,000 shares of the biotechnology company’s stock, valued at approximately $1,300,000. Armistice Capital LLC owned 9.46% of Aptose Biosciences as of its most recent SEC filing. Institutional investors own 26.62% of the company’s stock.

Aptose Biosciences Company Profile

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.